Geode Capital Management LLC Grows Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Geode Capital Management LLC boosted its position in Grifols, S.A. (NASDAQ:GRFS) by 56.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 110,532 shares of the biotechnology company’s stock after purchasing an additional 39,733 shares during the quarter. Geode Capital Management LLC’s holdings in Grifols were worth $982,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GRFS. GAMMA Investing LLC raised its holdings in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the period. Signaturefd LLC increased its holdings in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new position in Grifols in the second quarter valued at approximately $89,000. HighTower Advisors LLC grew its position in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares during the period. Finally, Chesapeake Capital Corp IL acquired a new stake in Grifols during the third quarter worth $148,000.

Grifols Trading Down 4.1 %

Shares of GRFS stock opened at $7.29 on Friday. The company has a 50-day moving average of $8.08 and a two-hundred day moving average of $8.16. The firm has a market cap of $5.01 billion, a PE ratio of 5.98 and a beta of 0.41. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $9.96. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.